Research Areas and Applications of Liraglutide Peptide (NN2211), CAS: 204656-20-2 Obesity and weight management research: Investigated as an anti-obesity agent that promotes satiety, reduces appetite, and supports sustainable weight loss alongside dietary and lifestyle interventions (e.g., Saxenda)
[12] [13] Readers should note that direct head-to-head comparisons with GLP-1 monotherapy agents have not been conducted
Other long-term considerations include: Muscle loss: Weight loss from GLP-1 medications isnt always just fat loss
TRIUMPH-3 Retatrutide Results: 22.6% at 12 mg TRIUMPH-3 reported topline results on July 23, 2026 22.6% weight loss at 12 mg over 80 weeks in a cardiovascular-disease population
These effects may support mindful portion sizes and long-term weight management when combined with healthy lifestyle habits
observed reversal of diastolic ventricular dysfunction in a rat model due DPP4 inhibition, via local actions on angiogenesis and inotropic effects [76]